Polyarticular Juvenile Idiopathic Arthritis (PJIA): 2018 Pipeline Review, H1 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

DUBLIN--()--The "Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 4, 9 and 2 respectively.

Companies Mentioned

  • Biocon Ltd
  • Coherus BioSciences Inc
  • Fresenius SE & Co KGaA
  • Genor BioPharma Co Ltd
  • Livzon Pharmaceutical Group Inc
  • Momenta Pharmaceuticals Inc
  • Mycenax Biotech Inc
  • Oncobiologics Inc
  • Oncodesign SA
  • Regeneron Pharmaceuticals Inc
  • Sandoz International GmbH
  • UCB SA

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Overview
  4. Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Companies Involved in Therapeutics Development
  14. Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Drug Profiles
  15. Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects
  16. Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Product Development Milestones
  17. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/76vg3v/polyarticular?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs